AstraZeneca says adding to capivasertib to Faslodex reduces breast cancer progression
jetcityimage


Adding AstraZeneca's (NASDAQ:AZN) experimental cancer drug capivasertib to Faslodex (fulvestrant) led to a 40% reduction in the risk of disease progression or death compared to Faslodex alone.
Results from the phase 3 CAPItello-291 trial indicated that progression-free survival was 7.2 months in the combination cohort vs. 3.6 months in the Faslodex alone group.

The objective response rate was 22.9% in the combination arm and 12.2% in other other.
Participants had HR-positive, HER2-low or negative locally advanced or metastatic breast cancer.
AstraZeneca (AZN) noted that although overall survival data is immature, early data is encouraging.
The pharma on Thursday also released positive data on camizestrant in breast cancer.